Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
Top Page
Imunon
(NASDAQ:IMNN)
Select Model
Select Model
Rating:41Neutral
Price Target:―
Imunon's financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock's risky profile, with a negative P/E ratio and no dividend yield.
Positive Factors
Clinical Progress
The successful Phase 2 study results for Imunon-001 indicate strong clinical progress, enhancing the company's prospects for future product approval and commercialization in oncology.
Regulatory Advancement
FDA's supportive feedback for the Phase 3 study initiation reflects regulatory confidence in Imunon's clinical strategy, potentially accelerating market entry and revenue generation.
Leadership Strength
Dr. Faller's appointment strengthens Imunon's leadership, leveraging his extensive experience to enhance clinical strategy and drive the company's pipeline towards commercialization.
Negative Factors
Financial Instability
Persistent financial challenges, including negative revenue and cash flow, undermine Imunon's operational stability and long-term financial health, necessitating strategic restructuring.
Cash Runway Concerns
Limited cash runway highlights liquidity risks, potentially hindering Imunon's ability to sustain operations and fund ongoing clinical trials without securing additional financing.
High Leverage
High leverage suggests financial strain, limiting Imunon's flexibility to invest in growth opportunities and increasing vulnerability to market fluctuations.
Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.56M
Dividend YieldN/A
Average Volume (3M)73.07K
Price to Earnings (P/E)―
Beta (1Y)-0.50
Revenue GrowthN/A
EPS Growth45.96%
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding2,521,206
10 Day Avg. Volume99,747
30 Day Avg. Volume73,074
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue16.22
Enterprise Value/Gross Profit-62.63
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$210.00Price Target Upside4116.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Imunon Business Overview & Revenue Model
Company DescriptionImunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
How the Company Makes MoneyImunon generates revenue primarily through the development and commercialization of its proprietary therapeutic and vaccine solutions. The company may engage in licensing agreements, where it partners with other pharmaceutical or biotechnology firms to co-develop or distribute its products, thereby earning licensing fees and royalties. Additionally, Imunon may receive funding from government grants or research collaborations, which contribute to its research and development efforts. By advancing its pipeline of candidates through clinical trials and achieving regulatory approvals, Imunon positions itself to earn revenue from product sales, either directly or through strategic partnerships.
Imunon Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
IMUNON's earnings call highlighted significant progress in its ovarian cancer treatment and the strong start of the Phase III OVATION 3 trial. The company is effectively managing costs and enhancing shareholder value through a stock dividend. However, it faces challenges in the capital markets, requiring ongoing efforts to secure additional funding.Q2-2025 Updates
Positive Updates
Significant Improvement in Ovarian Cancer Treatment
IMUNON's IMNN-001 therapy showed a median increase in overall survival of 13 months, a 45% improvement, in ovarian cancer patients when combined with standard care chemotherapy.
Phase III OVATION 3 Trial Progress
The OVATION 3 trial has had a strong start, opening sites faster than industry benchmarks, and has already enrolled its first patient. The trial is poised to redefine treatment for advanced ovarian cancer.
Stock Dividend to Enhance Shareholder Value
IMUNON announced a 15% stock dividend to boost shareholder value and confidence in the company's growth potential.
Cost Reduction and Financial Management
Operating expenses declined significantly, with R&D expenses dropping from $2.8 million to $1.2 million, and G&A expenses from $2.2 million to $1.5 million.
Negative Updates
Challenging Capital Markets Environment
IMUNON is facing a difficult capital market environment, impacting its funding strategies and necessitating careful financial management.
Ongoing Need for Additional Funding
While managing costs effectively, IMUNON continues to seek partnerships and additional funding to support its Phase III trial and strategic objectives.
Company Guidance
During the call, IMUNON provided detailed guidance on the progress and future plans for its lead candidate, IMNN-001, a gene-mediated IL-12 therapy for ovarian cancer. The OVATION 2 study showed a median increase in overall survival of 13 months, with a 45% improvement compared to the standard of care alone, and a hazard ratio of 0.69. The use of PARP inhibitors further enhanced outcomes, with median overall survival not yet reached in the IMNN-001 treatment arm after more than five years. The Phase III OVATION 3 trial is underway, with a primary endpoint of overall survival and secondary endpoints including surgical response score, chemotherapy response score, and time to second-line treatment. The trial began with three activated sites and has already randomized and treated its first patient. The company announced a strategy to fund OVATION 3 through partnerships and equity, and recently raised over $3 million through warrant exercises and ATM sales, while also implementing cost-saving measures to extend its cash runway.Imunon Financial Statement Overview
Summary
Imunon faces significant financial challenges, as indicated by consistently negative revenue, profitability, and cash flow metrics. High leverage and negative returns further exacerbate financial instability. The company needs strategic financial restructuring and improved operational performance to enhance its financial health and investor confidence.Income Statement
Imunon has consistently reported zero or negative revenue over the past years. Gross profit margins are nonexistent, with significant net losses indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, showing a lack of operational efficiency. There is no evidence of revenue growth, suggesting challenges in achieving market penetration or product commercialization.10
Very Negative
Balance Sheet
The company exhibits a relatively high debt-to-equity ratio, indicating reliance on debt financing. Return on Equity (ROE) is negative, reflecting ongoing net losses. The equity ratio shows some equity presence but is overshadowed by continuous financial strain. The balance sheet stability is questionable due to high leverage and negative equity returns.25
Negative
Cash Flow
Operating cash flow is consistently negative, reflecting poor cash generation from operations. Free cash flow is also negative, indicating insufficient cash to cover capital expenditures. Despite some positive financing and investing cash flow activities, the company's overall cash flow position is weak, raising concerns about liquidity and future operational funding.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 727.16K | 0.00 | 0.00 | 500.00K | 500.00K | 500.00K |
| Gross Profit | -188.27K | -718.12K | 0.00 | 500.00K | 500.00K | 500.00K |
| EBITDA | -15.07M | -17.98M | -19.88M | -31.71M | -20.88M | -21.30M |
| Net Income | -15.75M | -18.62M | -19.51M | -35.90M | -20.77M | -21.48M |
Balance Sheet | ||||||
| Total Assets | 8.79M | 9.72M | 21.92M | 43.98M | 74.05M | 37.53M |
| Cash, Cash Equivalents and Short-Term Investments | 4.73M | 5.87M | 15.70M | 32.75M | 49.39M | 17.16M |
| Total Debt | 1.19M | 1.14M | 1.62M | 6.27M | 6.63M | 6.19M |
| Total Liabilities | 6.13M | 5.47M | 8.53M | 14.65M | 18.25M | 18.92M |
| Stockholders Equity | 2.66M | 4.24M | 13.39M | 29.33M | 55.80M | 18.61M |
Cash Flow | ||||||
| Free Cash Flow | -14.57M | -18.88M | -19.47M | -23.36M | -16.54M | -15.64M |
| Operating Cash Flow | -14.27M | -18.85M | -19.02M | -23.10M | -16.22M | -15.62M |
| Investing Cash Flow | -294.77K | 9.83M | 11.01M | 8.28M | -30.12M | 7.92M |
| Financing Cash Flow | 13.99M | 9.06M | -3.64M | 6.72M | 54.77M | 17.98M |
Imunon Technical Analysis
Negative
4.98
Price Trends
6.47
Negative
10.16
Negative
10.94
Negative
Market Momentum
-0.50
Negative
28.06
Positive
13.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 4.98 is below the 20-day moving average (MA) of 5.75, below the 50-day MA of 6.47, and below the 200-day MA of 10.94, indicating a bearish trend. The MACD of -0.50 indicates Negative momentum. The RSI at 28.06 is Positive, neither overbought nor oversold. The STOCH value of 13.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.
Imunon Risk Analysis
Imunon disclosed 4 risk factors in its most recent earnings report. Imunon reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Any market activity involving short selling or other market making activities could result in negative impact to the market price for our Common Stock. Q2, 2025
2.
Our Common Stock may be delisted from Nasdaq if we fail to comply with continued listing standards. Q2, 2025
3.
We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without significant dilutive financing transactions, or at all. If we are not able to raise additional capital, we may not be able to complete the development, testing and commercialization of our drug candidates and will not be able to continue as a going concern. Q2, 2025
Imunon Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | 11.57M | -1.10 | 0.00% | ― | 247.62% | -7.66% | |
42 Neutral | 11.85M | -0.62 | 0.00% | ― | 0.00% | 85.26% | |
41 Neutral | $12.56M | ― | -491.97% | ― | ― | 45.96% | |
41 Neutral | 91.95M | -0.59 | 0.00% | ― | -100.00% | -221.06% | |
40 Underperform | 17.34M | -1.08 | 0.00% | ― | 0.00% | 29.97% | |
34 Underperform | 9.08M | -0.19 | 0.00% | ― | 0.00% | 58.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
IMNN
Imunon
4.98
-8.45
-62.92%
LITS
Lite Strategy
2.80
-0.13
-4.44%
PHIO
Phio Pharmaceuticals
2.07
-1.36
-39.65%
COCP
Cocrystal Pharma
1.33
-0.46
-25.70%
BRTX
BioRestorative Therapies
1.45
-0.36
-19.89%
INAB
IN8bio
2.00
-7.24
-78.35%
Imunon Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Imunon Appoints Dr. Douglas Faller as CMO
Positive
Feb 10, 2025
On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.